Corcept Therapeutics reported $115.75M in EBITDA for its fiscal quarter ending in September of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
ANI Pharmaceuticals USD 83.3M 11.7M Sep/2026
Ardelyx USD -9.78M 19.98M Jun/2026
Aurora Cannabis CAD 799K 2.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Canopy Growth CAD 8M 145M Jun/2026
Corcept Therapeutics USD 115.75M 73.59M Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
J&J USD 8.99B 721M Jun/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Merck USD 1.42B 2.97B Jun/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 8.62B 2.14B Sep/2026
Novartis USD 5.36B 45M Sep/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 50.45M 1.78M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Supernus Pharmaceuticals USD 55.6M 24M Sep/2026
TG Therapeutics USD 89.8M 62.9M Sep/2026